# A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

> **NCT04846920** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 52 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT04846920
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-14
- **Primary completion:** 2026-07-21
- **Final completion:** 2026-07-21
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846920, "A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04846920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*